JP2025503339A5 - - Google Patents
Info
- Publication number
- JP2025503339A5 JP2025503339A5 JP2024540899A JP2024540899A JP2025503339A5 JP 2025503339 A5 JP2025503339 A5 JP 2025503339A5 JP 2024540899 A JP2024540899 A JP 2024540899A JP 2024540899 A JP2024540899 A JP 2024540899A JP 2025503339 A5 JP2025503339 A5 JP 2025503339A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- optionally
- pharmaceutical composition
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266548P | 2022-01-07 | 2022-01-07 | |
| US63/266,548 | 2022-01-07 | ||
| PCT/US2023/060206 WO2023133485A2 (en) | 2022-01-07 | 2023-01-06 | Compositions and methods for treatment of thyroid eye disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503339A JP2025503339A (ja) | 2025-02-03 |
| JP2025503339A5 true JP2025503339A5 (enExample) | 2026-01-16 |
Family
ID=87074297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540899A Pending JP2025503339A (ja) | 2022-01-07 | 2023-01-06 | 甲状腺眼疾患を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240360227A1 (enExample) |
| EP (1) | EP4460524A4 (enExample) |
| JP (1) | JP2025503339A (enExample) |
| KR (1) | KR20240130134A (enExample) |
| CN (1) | CN118679187A (enExample) |
| AU (1) | AU2023205915A1 (enExample) |
| MX (1) | MX2024008530A (enExample) |
| WO (1) | WO2023133485A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| AU2024287547A1 (en) | 2023-07-07 | 2026-01-22 | Viridian Therapeutics, Inc. | Methods of treating chronic thyroid eye disease |
| WO2025051229A1 (zh) * | 2023-09-08 | 2025-03-13 | 北京拓界生物医药科技有限公司 | Igf-1r及tshr结合蛋白及其医药用途 |
| WO2025136985A1 (en) * | 2023-12-17 | 2025-06-26 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| EP1957541A2 (en) * | 2005-11-21 | 2008-08-20 | Laboratoires Serono SA | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| WO2013169611A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
-
2023
- 2023-01-06 WO PCT/US2023/060206 patent/WO2023133485A2/en not_active Ceased
- 2023-01-06 MX MX2024008530A patent/MX2024008530A/es unknown
- 2023-01-06 JP JP2024540899A patent/JP2025503339A/ja active Pending
- 2023-01-06 EP EP23737768.4A patent/EP4460524A4/en active Pending
- 2023-01-06 AU AU2023205915A patent/AU2023205915A1/en active Pending
- 2023-01-06 KR KR1020247026159A patent/KR20240130134A/ko active Pending
- 2023-01-06 CN CN202380021098.6A patent/CN118679187A/zh active Pending
-
2024
- 2024-07-01 US US18/760,539 patent/US20240360227A1/en active Pending